Royalty Pharma Plc · NASDAQ:RPRX

Royalty Pharma — Investor Presentation (December 2025)

6 slides from Royalty Pharma's investor presentation, December 2025

  1. Slide 1: Tividenofusp alfa synthetic royalty

    Tividenofusp alfa synthetic royalty December 2025

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete o

  3. Slide 3: Tividenofusp alfa synthetic royalty funding

    3 Tividenofusp alfa synthetic royalty funding 1 2 3 Denali’s tividenofusp alfa for First potential FDA-approved therapy Established market opportunity Hunter syndrome (MPS II) for MPS II addressing brain & periphery Hunter syndrome: genetic orphan Elaprase (standard of care enzyme >2,000 patients gl

  4. Slide 4: Acquired synthetic royalty on tividenofusp alfa for Hunter syndrome

    4 Acquired synthetic royalty on tividenofusp alfa for Hunter syndrome Up to $275m to acquire a royalty on Denali’s tividenofusp alfa Tividenofusp alfa consensus sales(2) ($ in millions) • $200m payment to Denali on FDA accelerated approval and $75m $575 on EMA approval if achieved by December 31, 20

  5. Slide 5: Phase 1/2 clinical results support potential for accelerated approval

    5 Phase 1/2 clinical results support potential for accelerated approval Tividenofusp alfa achieved normalization of key brain biomarkers in addition to gains on measures of peripheral disease Denali’s TransportVehicle (TV) platform CSF Heparan Sulfate Serum NfL (Engineered to optimize brain delivery

  6. Slide 6: Tividenofusp alfa – addressing significant unmet patient need

    6 Tividenofusp alfa – addressing significant unmet patient need Ultra rare disease Neurological symptoms Low life expectancy Validated market (1) (1) (3) (4) Market >2,000 >2/3t ~33 yrs $650m dynamics (patients globally) patients (of patients s have neurological disease) (median survival) (Elaprase

Royalty Pharma — Investor Presentation (December 2025) on 6ix